Ghassan K. Abou‐Alfa

Research interests

Publications

• The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment

  The Lancet · 2025 · https://doi.org/10.1016/s0140-6736(25)01042-6

• Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

  Annals of Oncology · 2024 · https://doi.org/10.1016/j.annonc.2024.02.005

• The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

  ESMO Open · 2023 · https://doi.org/10.1016/j.esmoop.2023.101567

• Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

  The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00242-5

• Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

  Journal of Clinical Oncology · 2022 · https://doi.org/10.1200/jco.2022.40.4_suppl.379

• Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

  Cell · 2022 · https://doi.org/10.1016/j.cell.2022.01.003

• Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

  NEJM Evidence · 2022 · https://doi.org/10.1056/evidoa2100070

• Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.03555

• Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation

  JAMA Oncology · 2021 · https://doi.org/10.1001/jamaoncol.2021.3836

• Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

  ˜The œLancet. Gastroenterology & hepatology · 2021 · https://doi.org/10.1016/s2468-1253(21)00196-5

• Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30157-1

• Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30109-1

• Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy101

• Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1717002

• Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2017.75.5009

• Intrahepatic Cholangiocarcinoma

  Annals of Surgery · 2008 · https://doi.org/10.1097/sla.0b013e318176c4d3

Current projects

No projects listed.